Home | Health | CHMP backs Novartis's Zykadia for first-line use in lung cancer

CHMP backs Novartis's Zykadia for first-line use in lung cancer

A sign marks a building on Novartis’ campus in Cambridge, Massachusetts, U.S., February 28, 2017. Picture taken February 28, 2017.

REUTERS/Brian Snyder

Click here to Read from the source

antalya oto kiralama Google
x

Check Also

Puma Biotech shares soar on optimism over cancer drug approval

0SHARESShare Puma Biotechnology’s experimental breast cancer drug appears to be effective, though there is some ...

Shares
sunexpress